Airtel's Nxtra raises renewable energy sourcing deal with Ampin to 200 MW
The additional capacity will be delivered to Nxtra in two phases, each through captive solar-wind power projects in Rajasthan and Karnataka, respectively, the statement said.
"This achievement highlights our leadership in using ISTS-backed clean energy to power our facilities sustainably, boosting reliability and ensuring tangible climate impact," Nxtra by Airtel, CEO, Ashish Arora said.
Ampin has been supplying solar power to Nxtra through intra-state, open access in Uttar Pradesh, Maharashtra and Odisha.
With this new agreement, AMPIN will add 11 new states as well as new technologies such as large-scale ISTS renewable energy supply and the seamless supply of renewable energy from a single Independent Power Producer (IPP).
"With this partnership, we demonstrate that through a seamless blend of inter-state and intra-state renewable energy solutions backed by a pan-India presence, we can take any customer through a nearly 100 per cent energy transition.
"Nxtra by Airtel, a leader in the data and fast-growing data centrespace shares our vision for sustainability and we are proud to make data centres green by this association," Pinaki Bhattacharyya, Founder, MD and CEO, AMPIN Energy Transition, said.
Nxtra joined the global RE100 initiative in June 2024, pledging to source 100 per cent of its electricity from renewable sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
31 minutes ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
Time of India
44 minutes ago
- Time of India
Promoters of CleanMax raise Rs 400 crore in pre-IPO round
Mumbai: Promoters of the Brookfield Corp-backed renewable energy company, CleanMax , have raised ₹400 crore from 360 One Asset Management to increase shareholding in the company in a pre-IPO funding completed last month. Founder Kuldeep Jain will raise stake from 14% to 21%. The money raised at 13% interest for 3 years will be repaid from IPO proceeds, people familiar with matter said. "The promoter is looking to fortify his stake before the imminent listing, the DHRP of which is likely to be filed later this year," said a person. "The increase in stake through private transactions will ensure promoter stake remains around 15% even after a likely offer for sale in the IPO." A CleanMax spokesperson did not respond to an email seeking comment. A 360 One spokesperson said he had no comments to offer to ET's email query. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program ETMarkets WhatsApp channel )
Economic Times
4 hours ago
- Economic Times
Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door?
Synopsis Bullish IPO 2025 is making headlines as the Peter Thiel-backed crypto exchange prepares for a massive $4.2 billion debut on the NYSE. With strong support from Wall Street giants like J.P. Morgan and interest from BlackRock and ARK, Bullish is setting the tone for a new era of institutional crypto investing. The company's regulatory-compliant model, massive $3B+ asset reserve, and strategy to convert IPO funds into stablecoins make it stand out. Backed by CoinDesk and built for serious traders, Bullish could redefine crypto's role in traditional finance. Reuters Bullish, the Peter Thiel-backed crypto exchange, is officially stepping onto Wall Street with a bold IPO move. Targeting a massive $4.2 billion valuation, the company plans to raise up to $629 million by offering over 20 million shares on the New York Stock Exchange under the ticker BLSH. With major underwriters like J.P. Morgan and Citi onboard, this listing marks one of the most significant U.S. crypto IPOs in years—signaling what could be the start of a powerful new wave for digital asset firms in public markets. Bullish aims for Wall Street spotlight with major IPO as crypto markets rebound- Bullish, the cryptocurrency exchange backed by billionaire tech mogul Peter Thiel, is gearing up for a major move on Wall Street, targeting a $4.2 billion valuation in its highly anticipated IPO debut on the New York Stock Exchange (NYSE). This IPO marks one of the most significant crypto stock market listings since Coinbase's 2021 launch and signals a new chapter for digital assets in the public investment space. As institutional investors warm up to crypto again, thanks to clearer U.S. regulations, Bullish's entry into the stock market could set the tone for the next wave of crypto IPOs in 2025. Bullish plans to raise up to $629 million through its U.S. IPO by offering approximately 20.3 million shares to the public, priced between $28 and $31 per share. There's also a 30-day option for underwriters to purchase an additional 3.05 million shares, potentially pushing the total raised even higher. The IPO, which will trade under the ticker 'BLSH', is being led by major investment banks J.P. Morgan, Citigroup, and Jefferies. This trio of top-tier underwriters signals strong Wall Street confidence in Bullish's business model and long-term vision. The timing of this IPO couldn't be more strategic. After years of uncertainty, the U.S. crypto space is finally finding its regulatory footing. The recent passage of the GENIUS Act, which sets out clear rules for stablecoins and crypto exchanges, is boosting investor confidence across the board. Bullish, unlike many other platforms, has focused on full regulatory compliance, institutional-grade operations, and financial transparency—three things that traditional investors now demand in the post-FTX world. The exchange's emphasis on security, deep liquidity, and asset transparency gives it a competitive edge as it enters public markets. Bullish is not your average crypto exchange. Unlike Robinhood, Binance, or meme coin-centric platforms, Bullish is built for institutional trading. It offers deep order books, high liquidity, and secure asset custody systems that attract professional traders and large institutions rather than speculative retail players. One standout feature is its ownership of CoinDesk, a top-tier crypto media company acquired in 2023 for about $70 million. This allows Bullish to not only operate as a trading platform but also influence the narrative in crypto markets through strategic media visibility—something no other exchange has done at this scale. The presence of Peter Thiel as a lead backer adds significant weight to Bullish's reputation. As co-founder of PayPal and Palantir, Thiel's involvement lends Bullish the same disruptive tech DNA that made those firms Wall Street successes. Bullish is also supported by a powerful syndicate of investors, including Founders Fund, Galaxy Digital, and Japanese banking giant Nomura. This global backing gives the exchange both geographic reach and financial clout—two key advantages as it scales operations post-IPO. Unlike many companies that simply add IPO funds to their balance sheet, Bullish plans a more strategic move. A large portion of the net IPO proceeds will be converted into U.S. dollar-backed stablecoins, helping to reduce exposure to crypto market volatility and enhance overall platform liquidity. This decision aligns with the provisions of the GENIUS Act, showing regulators and investors alike that Bullish is serious about stable, compliant growth. As of its IPO filing, Bullish holds a massive $3+ billion in liquid assets. That includes: 24,000 Bitcoin (BTC) 12,600 Ethereum (ETH) Over $400 million in stablecoins and cash This robust balance sheet gives Bullish a serious financial advantage over many of its peers, enabling it to offer better pricing, handle larger trades, and remain resilient during market downturns. Back in 2021, Bullish had attempted to go public via a SPAC merger with Far Peak Acquisition Corp, which would have valued the company at $9 billion. That deal was eventually scrapped in 2022 amid crypto market instability and unclear regulations. Now, with stronger financials and regulatory clarity, Bullish is taking a more realistic approach. Its current IPO target of $4.2 billion may be lower than past ambitions, but it's far more aligned with today's market environment and investor expectations. Institutional appetite for Bullish shares appears to be heating up. Both BlackRock and ARK Investment Management have expressed non-binding interest in investing up to $200 million at the IPO price. While not yet confirmed, this level of potential commitment from two of the world's most influential asset managers is a major vote of confidence. If these firms follow through, Bullish could attract even more institutional attention—and likely outperform expectations in its debut week on the NYSE. This IPO could set the stage for a new wave of crypto companies entering the U.S. public markets. Industry leaders like Circle, eToro, Kraken, and OKX are reportedly preparing IPOs of their own, and Bullish's performance will likely become a benchmark for the entire sector. Investors, regulators, and crypto advocates alike will be watching closely to see if Bullish can bridge the gap between traditional finance and digital assets—something many platforms have tried and failed to do. Bullish confidentially filed with the SEC in June and made its public filing on August 4, 2025. The IPO roadshow began shortly after, with pricing expected in the week of August 11, according to industry insiders. With the listing set for later in August, the next few weeks will be critical for final investor commitments and pricing momentum. The Bullish IPO is shaping up to be one of the most important tech listings of 2025—not just for crypto, but for the broader financial sector. Backed by elite investors, flush with liquidity, and positioned perfectly in a newly compliant U.S. regulatory framework, Bullish has all the ingredients of a breakout success. Whether you're a long-term crypto believer or a traditional investor exploring digital assets for the first time, Bullish stock is one to watch closely. It's more than a crypto company—it's a financial infrastructure play, and one that could help shape the future of how digital assets trade, move, and are regulated in mainstream markets. Company : Bullish Global : Bullish Global IPO Valuation Target : $4.2 billion (fully diluted at $31/share) : $4.2 billion (fully diluted at $31/share) Ticker Symbol : BLSH (NYSE) : BLSH (NYSE) Price Range : $28–$31 per share : $28–$31 per share Shares Offered : 20.3 million (plus 3.05 million overallotment) : 20.3 million (plus 3.05 million overallotment) Capital Raised (Est.) : Up to $629 million : Up to $629 million Lead Underwriters : J.P. Morgan, Citigroup, Jefferies : J.P. Morgan, Citigroup, Jefferies Use of Proceeds : Conversion into stablecoins, liquidity enhancement : Conversion into stablecoins, liquidity enhancement Institutional Interest : BlackRock, ARK (non-binding interest up to $200 million) : BlackRock, ARK (non-binding interest up to $200 million) Liquid Assets : $3B+ (BTC, ETH, cash, stablecoins) : $3B+ (BTC, ETH, cash, stablecoins) CoinDesk Acquisition: Completed in 2023 (~$70M) If Bullish delivers on its promises, this IPO could become a pivotal moment in crypto's path to institutional acceptance and long-term sustainability. Q1: What is the Bullish IPO 2025 all about? It's a crypto exchange backed by Peter Thiel going public with a $4.2B valuation on NYSE. Q2: Why is Bullish's IPO getting attention from investors? Because it's fully regulated, holds $3B+ in assets, and is backed by BlackRock and ARK.
